Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Fong

Showing results (161-170 of 198) with videos related to

Pageof 20
Sort By:
Prostate Cancer and Prostatic Diseases|July 14, 2021
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancerCharles G Drake, Russell K Pachynski, Sumit K Subudhi, et al.
Journal for Immunotherapy of Cancer|April 20, 2024
Dysregulation of CD4<sup>+</sup> and CD8<sup>+</sup> resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitisJun Yan He, Yang-Joon Kim, Elvira Mennillo, et al.
Journal for Immunotherapy of Cancer|August 28, 2021
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)Russell K Pachynski, Chihiro Morishima, Russell Szmulewitz, et al.
The New England Journal of Medicine|February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.
Journal for Immunotherapy of Cancer|May 13, 2021
<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitorIvan de Kouchkovsky, Li Zhang, Errol J Philip, et al.
Science Translational Medicine|June 19, 2015
Transglutaminase 4 as a prostate autoantigen in male subfertilityNils Landegren, Donald Sharon, Anthony K Shum, et al.
The Journal of Clinical Investigation|December 12, 2018
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicityChien-Chun Steven Pai, Donald M Simons, Xiaoqing Lu, et al.
Journal for Immunotherapy of Cancer|February 20, 2021
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumorsJason J Luke, Fabrice Barlesi, Ki Chung, et al.
Frontiers in Oncology|March 24, 2022
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial CancerDivya Natesan, Li Zhang, Henry J Martell, et al.
JAMA Oncology|June 3, 2019
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 StudyThomas S Uldrick, Priscila H Gonçalves, Maher Abdul-Hay, et al.
Pageof 20

Showing results (161-170 of 198) with videos related to

Sort By:
Pageof 20
Prostate Cancer and Prostatic Diseases|July 14, 2021
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancerCharles G Drake, Russell K Pachynski, Sumit K Subudhi, et al.
Journal for Immunotherapy of Cancer|April 20, 2024
Dysregulation of CD4<sup>+</sup> and CD8<sup>+</sup> resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitisJun Yan He, Yang-Joon Kim, Elvira Mennillo, et al.
Journal for Immunotherapy of Cancer|August 28, 2021
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)Russell K Pachynski, Chihiro Morishima, Russell Szmulewitz, et al.
The New England Journal of Medicine|February 18, 2017
Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaJoaquim Bellmunt, Ronald de Wit, David J Vaughn, et al.
Journal for Immunotherapy of Cancer|May 13, 2021
<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitorIvan de Kouchkovsky, Li Zhang, Errol J Philip, et al.
Science Translational Medicine|June 19, 2015
Transglutaminase 4 as a prostate autoantigen in male subfertilityNils Landegren, Donald Sharon, Anthony K Shum, et al.
The Journal of Clinical Investigation|December 12, 2018
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicityChien-Chun Steven Pai, Donald M Simons, Xiaoqing Lu, et al.
Journal for Immunotherapy of Cancer|February 20, 2021
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumorsJason J Luke, Fabrice Barlesi, Ki Chung, et al.
Frontiers in Oncology|March 24, 2022
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial CancerDivya Natesan, Li Zhang, Henry J Martell, et al.
JAMA Oncology|June 3, 2019
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 StudyThomas S Uldrick, Priscila H Gonçalves, Maher Abdul-Hay, et al.
Pageof 20